Aflac Incorporated (NYSE:AFL) Director Sells $3,197,456.58 in Stock

Aflac Incorporated (NYSE:AFL) Director Charles D. Lake II sold 29,802 shares of Aflac stock in a transaction on Monday, March 10th. The stock was sold at an average price of $107.29, for a total transaction of $3,197,456.58. Following the transaction, the director now directly owns 49,962 shares of the company’s stock, valued at $5,360,422.98. This represents a 37.36 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Aflac Price Performance

Shares of AFL stock traded down $0.42 during trading hours on Tuesday, reaching $106.35. The stock had a trading volume of 2,050,322 shares, compared to its average volume of 2,020,688. The stock’s fifty day simple moving average is $105.15 and its 200 day simple moving average is $107.73. The company has a current ratio of 0.10, a quick ratio of 0.08 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $58.13 billion, a PE ratio of 11.08, a PEG ratio of 3.24 and a beta of 0.93. Aflac Incorporated has a 12 month low of $79.31 and a 12 month high of $115.50.

Aflac (NYSE:AFL) last announced its earnings results on Wednesday, February 5th. The financial services provider reported $1.56 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.07). Aflac had a return on equity of 16.20% and a net margin of 28.76%. On average, equities research analysts predict that Aflac Incorporated will post 6.88 EPS for the current year.

Institutional Investors Weigh In On Aflac

Institutional investors and hedge funds have recently bought and sold shares of the stock. Whipplewood Advisors LLC bought a new position in shares of Aflac in the 4th quarter worth $26,000. Darwin Wealth Management LLC purchased a new position in Aflac in the third quarter worth $34,000. BankPlus Trust Department bought a new position in Aflac in the fourth quarter valued at $34,000. Curio Wealth LLC purchased a new stake in Aflac during the fourth quarter valued at about $36,000. Finally, Raelipskie Partnership bought a new stake in Aflac during the third quarter worth about $38,000. 67.44% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AFL has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lifted their target price on Aflac from $90.00 to $94.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 7th. Barclays dropped their target price on shares of Aflac from $98.00 to $95.00 and set an “underweight” rating on the stock in a research note on Friday, February 7th. Morgan Stanley raised their price target on shares of Aflac from $98.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. StockNews.com upgraded Aflac from a “sell” rating to a “hold” rating in a research note on Friday, February 14th. Finally, BMO Capital Markets began coverage on Aflac in a research report on Thursday, January 23rd. They issued a “market perform” rating and a $111.00 target price for the company. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $103.36.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.